A pressure release assembly for a tubing set may include an engagement sleeve including an inner surface defining a cavity, the inner surface including a connection arrangement configured to connect the engagement sleeve to a tubing set, and a pin member configured to be received in the cavity of the engagement sleeve. The pin member may be movable between a first position in which the pin member is removed from a seal of the tubing set and a second position in which the pin member is inserted into the seal of the tubing set to allow air to be purged from the tubing set.
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/38 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body using hydrophilic or hydrophobic filters
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 39/00 - Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
The present invention relates to medical uses comprising the administration of anti-human CCR8 antibodies in specifically defined dosage regimens in monotherapy or combination therapy with an anti-PD-(L)1 antibody. The dosing schemes were developed for anti-human/cynomolgus CCR8 antibody TPP-23411, but they can also be used for other antibodies having similar properties as TPP-23411. The medical uses or dosage regimens may comprise a stratification step to select patients with an increased probability of treatment success. Suggested biomarkers are a) Tumor Proportion Score or Combined Positive Score as a measure for PD-(L)1 expression, b) analysing in a blood, plasma or serum sample inflammatory cytokines and c) previous treatment of the cancer for at least 6 months with an anti-PD-(L)1 antibody. Furthermore, provided are anti-human CCR8 antibody-based medical uses and treatment methods comprising the administration of a Zr-89-labeled anti-CD8 minibody to determine the abundance and/or distribution of CD8 cells by means of a PET scan for stratification or for monitoring treatment success or disease progression. Also provided is a method to reliably determine an anti-anti-CCR8 antibody in cynomolgus or human plasma. Finally, an anti-murine CCR8 surrogate antibody is disclosed that mimics the unusual half-life of TPP-23411.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
3.
SYSTEMS AND METHODS FOR GENERATING PROTOCOLS EMBODYING CONTRAST AND RADIATION DOSE MANAGEMENT TECHNIQUES
A system and method for generating protocols that can be used for medical imaging studies. The method can include receiving information about a subject patient and information about a subject imaging study; determining, based on the information about the subject patient and the information about the subject imaging study, one or more risk factors particular to the subject patient; selecting two or more models, wherein the two or more models include at least one model of each of at least two aspects of the subject imaging study; and applying the two or more models to generate a baseline study protocol for the subject imaging study. The baseline study protocol is based upon at least the information about the subject patient and the one or more risk factors. The baseline study protocol includes parameters of the at least two aspects of the subject imaging study.
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
4.
NAPROXEN SODIUM TABLETS PRODUCED USING A CONTINUOUS PROCESS
Provided are oral tablets comprising naproxen sodium, mannitol, a superdisintegrant, and a lubricant. The oral tablets described herein to not comprise a glidant (e.g. colloidal silicon dioxide). These oral tablets may be manufactured using the process of mixing naproxen sodium, mannitol, a superdisintegrant, and magnesium stearate in a continuous in-line mixer to form a tableting mixture; transferring the tableting mixture to a tablet press including three or more compression rollers; and pressing the tableting mixture into naproxen sodium tablets.
Provided is a disinfecting cap for a fluid path element having an inner lumen and an outer cylindrical wall surrounding the inner lumen. The disinfecting cap includes a housing configured to receive the inner lumen and the outer cylindrical wall of the fluid path element. The housing has an open proximal end, a closed distal end, and a sidewall extending between the open proximal end and the closed distal end to define an interior volume. A sleeve protrudes proximally from an inner surface of the closed distal end and defines an opening configured to receive the inner lumen of the fluid path element. A compressible absorbent material at least partially saturated with a disinfecting fluid is disposed within the interior volume of the housing and surrounding at least a portion of the sleeve.
Methods for providing one or more guided workflow features with regard to a fluid injector system, may include receiving data associated with the fluid injector system, displaying a first graphical user interface (GUI) screen associated with a guided workflow for operation of the fluid injector system on one or more display devices based on the data associated with one or more components of the fluid injector system, receiving a first user input, displaying a second GUI screen associated with the guided workflow on the one or more display devices based on receiving the first user input, executing a first operation of the fluid injector system, and receiving a second user input, where the second GUI screen provides information that is sequential to the first GUI screen with regard to the guided workflow for operation of the fluid injector system. Systems and computer program products are also disclosed.
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
7.
REMOVABLE DUST CAP AND TAMPER-EVIDENT FEATURE FOR SYRINGE
A fluid path connector assembly for a medical fluid delivery system includes a connector element having a body, a lumen extending through the body, and a pair of flexible legs connected to the body, each of the flexible legs having a flange. The connector assembly further includes a dust cap removably connected to the connector element. The dust cap includes a dust cap body positioned between the flexible legs to enclose the lumen, and an engagement element at a distal end of the dust cap body. The engagement element is in contact with the flanges of the flexible legs to prevent disengagement of the dust cap from the connector element while allowing ready removal of the dust cap by medical personnel. A removable/disconnectable tamper resistant and/or tamper-evident and/or tamper resistant feature connecting the dust cap to the connector element is also disclosed.
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
A system, method, and computer program product for implementing a remote console for use in diagnostic imaging may include a user interface and/or at least one processor programmed and/or configured to: receive, from at least one of an injection system including an injector configured to deliver fluid to a patient and an imaging system including a scanner configured to scan the patient, procedure data associated with a procedure for the patient, at least one of the injection system and the imaging system including at least one further user interface different than the user interface, and the injection system being in communication with the imaging system; provide, via the user interface, a display, the display being generated based on the procedure data; receive, via the user interface, user input; and control, based on the user input, an operation of at least one of the injection system and the imaging system.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
9.
SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR ASSOCIATING INJECTOR AND IMAGER PROTOCOLS
Disclosed herein are system, method, and computer program product embodiments for associating injector and imager protocols. For example, the method may include: receiving, from an imaging system including an imager configured to image a patient, imager protocol data associated with an imager protocol according to which the imaging system is configured to control imaging of the patient with the imager, the imaging system being in communication with an injection system including an injector configured to deliver fluid and/or imaging agent to the patient; receiving, via at least one user interface, at least one of a selection, a programming, a modification, or any combination thereof of an injector protocol according to which the injection system is configured to control delivery of at least one fluid and/or imaging agent to the patient with the injector; and associating, in at least one database, the imager protocol with the injector protocol.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
Devices, kits, and methods for heating a drug formulation in an injection device are disclosed. An embodiment of the device includes a housing enclosure having a first housing shell and a second housing shell, and a plurality of bladders adjacent to an inner surface of the first housing shell and adjacent to an inner surface of the second housing shell. The housing enclosure is designed to receive the injection device. When an edge of the first housing shell and an edge of the second housing shell couple, the bladders contact a portion of the injection device and heat the drug formulation in the injection device. An embodiment of the kit includes this device and the injection device.
A61M 5/44 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for cooling or heating the devices or media
Provided are child-proof stick packs comprising: a single sheet of film comprising two or more layers, wherein at least one layer comprises polyethylene terephthalate and faces an environment exterior to the stick pack; a laser-scored design on the film comprising a plurality of scores, wherein each score of the plurality of scores comprises an area in which the polyethylene terephthalate layer is weakened or removed from the film, wherein the stick pack comprises a bottom seal, a top seal, and a rear seal extending between the top seal and the bottom seal, is configured to contain one or more of an active pharmaceutical ingredient, therapeutic agent, or supplement and cannot be opened by more than 20% of children under the age of 5 years using only two hands.
B65D 50/00 - Closures with means for discouraging unauthorised opening or removal thereof, with or without indicating means, e.g. child-proof closures
B65D 75/00 - Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes, or webs of flexible sheet material, e.g. in folded wrappers
B65D 75/58 - Opening or contents-removing devices added or incorporated during package manufacture
A61J 1/03 - Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
B65D 65/40 - Applications of laminates for particular packaging purposes
12.
SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR MANAGING AUTOMATED HEALTHCARE DATA APPLICATIONS USING ARTIFICIAL INTELLIGENCE
Provided is a system for managing automated healthcare data applications using artificial intelligence (Al) that includes at least one processor programmed or configured to receive healthcare data from a data source, determine a classification of the healthcare data using a machine learning model, wherein the machine learning model is configured to provide a predicted classification of an automated healthcare data analysis application of a plurality of automated healthcare data analysis applications based on an input, and provide the healthcare data to an automated healthcare data analysis application based on the classification of the healthcare data. Methods and computer program products are also disclosed.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
13.
EXTENDED, HIGH DOSE VEGF ANTAGONIST REGIMENS FOR TREATMENT OF ANGIOGENIC EYE DISORDERS
The present invention relates to regimens for the treatment of angiogenic eye disorders such as DR and DME characterized by high doses of aflibercept and lengthening intervals between doses.
The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, characterized by high doses of aflibercept and extended intervals between doses.
A fluid injector system includes at least one fluid reservoir having a first fluid reservoir configured for injecting a radiopharmaceutical and a radiation filter in fluid communication with the at least one fluid reservoir. The radiation filter is configured for retaining radioactive particles from the radiopharmaceutical passing though the radiation filter. The system further includes at least one sensor configured to detect radioactivity in at least one of the first fluid reservoir, the radiation filter, and a fluid path element in fluid communication with the radiation filter; and a controller in operative communication with the at least one sensor. The controller is programmed or configured to receive a radioactivity measurement from the at least one sensor and determine, based on the radioactivity measurement, that an amount of radioactive particles in at least one of the first fluid reservoir, the radiation filter, and the fluid path set satisfies a predetermined threshold.
A61M 5/165 - Filtering accessories, e.g. blood filters, filters for infusion liquids
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
16.
SYSTEM, METHOD AND DEVICE FOR DELIVERY OF A THERAPEUTIC OR DIAGNOSTIC AGENT
Systems and methods for distribution, storage, transport, administration and/or disposal of one or more therapeutic or diagnostic agents are disclosed. A storage device configured to connect to a delivery system for delivering the therapeutic or diagnostic agent has a housing with a chamber, a vessel having an access port positioned within the chamber. The door is movable relative to the housing between a closed position and an open position. In the closed position, the door covers an opening in the housing to enclose the chamber, and, in the open position, the door reveals the opening for accessing the access port of the vessel. The door is moveable between the closed position and the open position in response to actuation by an access mechanism of the delivery system.
A61M 5/165 - Filtering accessories, e.g. blood filters, filters for infusion liquids
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
G21F 5/015 - Transportable or portable shielded containers for storing radioactive sources, e.g. source carriers for irradiation units; Radioisotope containers
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes - Details; Accessories therefor
17.
ADVANCED DATA-DRIVEN MODELING FOR PURIFICATION PROCESS IN BIOPHARMACEUTICAL MANUFACTURING
An exemplary method for assessing performance of an instance of a chemical process having a series of consecutive phases includes: obtaining data related to the instance of the chemical process; and evaluating, based on the data related to the instance of the chemical process, the performance of the instance of the chemical process using a plurality of performance thresholds, wherein the plurality of performance thresholds is obtained by training a hierarchical model based on one or more historical instances of the chemical process, and wherein the hierarchical model includes: a plurality of batch-evolution models (BEMs) at a first level of a hierarchy; a plurality of batch-level models (BLMs) at a second level above the first level of the hierarchy; and an overall performance model at a third level at a third level above the second level of the hierarchy.
G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
18.
AMMONIUM SULFATE TREATED SYRINGE FOR INCREASED PHARMACEUTICAL COMPOSITION STABILITY
Ammonium sulfate treated prefilled syringes, and kits that include an ammonium sulfate treated prefilled syringe and a pharmaceutical composition comprising an aluminum-sensitive active agent, are described herein. Treating the inner surface of a glass syringe barrel with ammonium sulfate prior to filling the syringe with a desired aqueous diluent, such as water for injection, can limit the amount of aluminum that leach into the aqueous diluent during storage.
C03C 17/30 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with organic material with silicon-containing compounds
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
2222-displaced, filtered cell culture fluid sample according to their size under non-denaturing conditions, and determining the disulfide bond reduction potential of the protein of interest.
The present disclosure relates generally to formulations for gastric and gastroesophageal disorders, such as gastroesophageal reflux disorder (GERD) acid reflux, peptic ulceration, acute and/or chronic gastritis, and other disorders, and more specifically to formulations comprising alginic acid or pharmaceutically acceptable salts thereof, pectin, and carrageenan. The liquid formulations described herein demonstrate long-lasting mucoadhesion and raft-forming ability. The present disclosure also provides methods of using the liquid formulations described herein for treatment of such gastric and gastroesophageal disorders.
The present disclosure relates generally to liquid formulations as a general delivery platform for active pharmaceutical ingredients, and more specifically to oral liquid formulations comprising alginic acid or pharmaceutically acceptable salts thereof, pectin and/or carrageenan for treatment of cough and cold. The present disclosure also provides methods of using the formulations described herein for treatment of cough and cold.
A fluid injector system includes at least one injector for pressurizing and delivering at least one fluid from at least one fluid reservoir, at least one fluid path section providing fluid communication between a bulk fluid reservoir and a syringe connected to the at least one injector, and at least one sensor arranged along the at least one fluid path section. The at least one sensor includes an emitter configured to emit light through the at least one fluid path section, and a detector configured to receive the light emitted through the at least one fluid path section and generate an electrical signal based on at least one property of the received light. The fluid injector system may further include at least one processor programmed or configured to determine, based on the electrical signal generated by the detector, at least one of an identity of the at least one fluid present in the fluid path section, a concentration of the at least one fluid in the fluid path section, and at least one property of the fluid path section.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
A61M 5/48 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for varying, regulating, indicating or limiting injection pressure
23.
EXTENDED, HIGH DOSE VEGF ANTAGONIST REGIMENS FOR TREATMENT OF ANGIOGENIC EYE DISORDERS
Described herein is method for purifying messenger RNA (mRNA) encoding a DNA endonuclease from a sample, the method comprising: (a) loading the sample comprising the mRNA onto a monolithic matrix comprising a poly(dT) or poly(U) nucleic acid molecule linked/coupled to the monolithic matrix under conditions allowing the mRNA to hybridize with the poly(dT) or poly(U) nucleic acid molecule; (b) eluting the mRNA from the monolith matrix after one or more contaminants have been separated from the bound mRNA; and (c) separating the mRNA from dsRNA by adsorption chromatography, thereby resulting in a purified mRNA solution.
A fluid injector system includes at least one injector for pressurizing and delivering at least one fluid from at least one fluid reservoir, at least one fluid path section in fluid communication with the at least one injector and having a predetermined index of refraction, and a first proximal sensor and a first distal sensor arranged along the at least one fluid path section. Each of the first proximal sensor and the first distal sensor includes an emitter configured to emit light through the at least one fluid path section, and a detector configured to receive the light emitted through the at least one fluid path section and generate an electrical signal based on the received light. The fluid injector system further includes at least one processor programmed or configured to determine, based on a difference in the electrical signals generated by the first proximal sensor and the first distal sensor, at least one property of a content of the at least one fluid path section.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
A61M 5/48 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for varying, regulating, indicating or limiting injection pressure
26.
METHODS OF ADJUSTING THE PH OF A CELL CULTURE MEDIUM
Methods for adjusting the pH of a cell culture medium, methods for culturing cells in a pH-adjusted cell culture medium, and methods for making a polypeptide expressed by cells cultured in a pH-adjusted cell culture medium are described. Also described are systems for determining how much acid or base should be added to a cell culture medium to obtain a desired pH. The methods include a charge balance model that includes parameters for a functional relationship between a concentration of dissolved carbon dioxide in the cell culture medium, a mole fraction of gaseous carbon dioxide applied to the cell culture medium, a concentration of net medium acids in the cell culture medium, and the desired medium pH.
A system, method, and computer program product for protocol conversion may obtain a fixed protocol including the following fixed protocol parameters: a flow rate of at least one fluid to be delivered to a patient in at least one phase of an injection and a volume of the at least one fluid to be delivered to the patient in the at least one phase of the injection; provide a series of prompts, and receive a series of user responses in response to the series of prompts; and generate, based on the series of user responses and the fixed protocol, a smart protocol including the following smart protocol parameters according to which the injection system is configured to control delivery of the at least one fluid to the patient in the injection: a dosing factor and a dosing method.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
28.
CONCENTRATED LIQUID GEL FORMULATIONS CONTAINING NAPROXEN SALTS
This disclosure is in the field of mini-softgel capsules, particularly softgel capsules containing naproxen salt as an active ingredient. It relates generally to softgel capsules containing high concentration formulations of naproxen sodium.
A cassette for holding fluid path components for a fluid injector may include a body defining at least one feature for holding at least one fluid path component for the fluid injector; and a connecting member for removably connecting the body of the cassette to the fluid injector, the connecting member operatively connected to the body, wherein the connecting member comprises at least one pivotable connecting feature protruding from the body, and wherein each of the at least one pivotable connecting feature is configured for removably connecting to a corresponding connecting feature receiver on the fluid injector such that the body is pivotally movable relative to the fluid injector between a first, unlatched position and a second, latched position in which the at least one fluid path component on the body of the cassette is positioned for operative connection to a corresponding feature of the fluid injector.
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
30.
ORAL BILAYER TABLETS COMPRISING ACETYLSALICYLIC ACID AND PSEUDOEPHEDRINE, METHODS OF PREPARING AND USING THEREOF
The present disclosure relates generally to bilayer tablets comprising a combination of two active pharmaceutical ingredients, and more specifically to bilayer tablets comprising acetylsalicylic acid, pseudoephedrine, and a dissolution aid. The bilayer tablets utilize a combination of granulated and non-granulated acetylsalicylic acid along with a unique distribution of sodium carbonate as a dissolution aid that provide acetylsalicylic acid and pseudoephedrine in a single dosage form having rapid dissolution and long-term storage stability (low degradation). The present disclosure also provides methods of preparing and of using the bilayer tablets.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/616 - Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
This disclosure relates to auto-injectors and their method of use with pre-filled syringes. The embodiments include an auto-injector system for injecting various solution volumes, including: an auto-injector housing having an actuating end and an injection end, the housing including; a release mechanism co-axially aligned in the housing near the actuating end; a spring co-axially aligned and in contact with the release mechanism; a pre-filled syringe co-axially aligned in the housing at the injection end, including a set capacity syringe barrel having a syringe chamber for holding a plunger cap with a plunger cap length and a solution volume for injecting, wherein the plunger cap retains the solution volume within the syringe chamber; and a syringe needle attached to the syringe barrel for injecting the solution volume; an interchangeable plunger rod that's interchangeable having a defined interchangeable plunger rod length and being co-axially aligned in the housing between the spring and the plunger cap; and an interchangeable plunger rod extension that's interchangeable having a defined interchangeable plunger rod extension length and being coaxially aligned and contacting the interchangeable plunger rod, wherein the lengths of the spring, interchangeable plunger rod, interchangeable plunger rod extension, and plunger cap define a co-axially aligned and continuous auto-injector system for injecting various solution volumes; and an optional auto-injector cap for covering the auto-injector housing at the injection end. The embodiments further provide methods for injecting various solution volumes using an auto-injector system, including: providing an auto-injector system for injecting various solution volumes, including an auto-injector housing having an actuating end and an injection end, the housing including a release mechanism co-axially aligned in the housing near the actuating end; a spring co-axially aligned and in contact with the release mechanism; a pre-filled syringe co-axially aligned in the housing at the injection end, including a set capacity syringe barrel having a syringe chamber for holding a plunger cap with a plunger cap length and a solution volume, wherein the plunger cap retains the solution volume within the syringe chamber; and a syringe needle attached to the syringe barrel for injecting the solution volume; an interchangeable plunger rod having a defined interchangeable plunger rod length and being co-axially aligned in the housing between the spring and the plunger cap; and an interchangeable plunger rod extension having a defined interchangeable plunger rod extension length and being co-axially aligned and contacting the interchangeable plunger rod, wherein the lengths of the spring, interchangeable plunger rod, interchangeable plunger rod extension, and plunger cap define a co-axially aligned and continuous auto-injector system for injecting various solution volumes; and an optional auto-injector cap for covering the auto-injector housing at the injection end; and injecting the various solution volumes.
A system for securely accessing a fluid injection system is disclosed. The system includes at least one processor programmed or configured to authenticate a user for access to an fluid injection system, provide data identifying one or more features of a software application for accessing the fluid injection system, receive data identifying a selected feature of the software application for accessing the fluid injection system, and provide access to the selected feature of the software application for accessing the fluid injection system.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
The present embodiments relate to pathogen clearance. Subject matter of the present embodiments are computer-implemented methods, computer systems and computer-readable storage media for predicting the performance of pathogen clearance processes.
C07K 1/16 - Extraction; Separation; Purification by chromatography
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
G16C 20/00 - Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
G16C 20/70 - Machine learning, data mining or chemometrics
A prime tube includes a sidewall defining an internal chamber having an expandable volume, a connecter associated with a proximal end of the sidewall and configured to reversibly engage an outlet of a fluid reservoir containing a medical fluid, and a closure associated with a distal end of the sidewall, the closure permeable to air and substantially impermeable to the medical fluid. The expandable volume of the internal chamber is configured to increase as the medical fluid enters the internal chamber.
A61M 5/38 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body using hydrophilic or hydrophobic filters
A61M 39/00 - Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
A syringe including a proximal end, a distal end, and a cylindrical sidewall extending between the proximal end and the distal end, wherein the distal end comprises a conical distal end wall and a fluid nozzle at a distal end of the conical distal end wall; a cylindrical load bearing wall extending axially from the cylindrical sidewall past a proximal end of the conical distal end wall; and a plurality of radial ribs positioned around a periphery of the conical distal end wall, wherein a longitudinal axis of the plurality of radial ribs extends radially inward from the cylindrical load bearing wall towards the fluid nozzle over at least a portion of the conical distal end wall.
Provided is a system for enabling communication between a fluid injection system and at least one of a plurality of external systems. The system includes a gateway device and the gateway device includes at least one processor programmed or configured to provide a first communication interface between a hospital information system and a fluid injection system, provide a second communication interface between a fluid injection system service and control system associated with the fluid injection system and the fluid injection system, and provide a third communication interface between a medical imaging system and the fluid injection system.
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the inventive antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the inventive antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti -human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-intemalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the inventive antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
40.
ANTI CCR8 ANTIBODY THERAPY: BIOMARKERS & COMBINATION THERAPIES
The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the inventive antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
An apparatus (300) for suspending air bubbles in a fluid path of a fluid injector system includes an internal chamber (320) having a curved interior wall (322) defined within the housing (310), an inlet fluid pathway in fluid communication with the internal chamber, and an outlet fluid pathway in fluid communication with the internal chamber. The inlet fluid pathway extending into the chamber at a tangent to the curved interior wall, and the outlet fluid pathway spaced from the inlet fluid pathway such that fluid flowing into the internal chamber via the inlet fluid pathway is directed away from the outlet fluid pathway. The internal chamber is configured to create an internal fluid vortex in an injection fluid entering the internal chamber from the inlet fluid pathway, and wherein the internal fluid vortex at least temporarily suspends air bubbles in the fluid in the internal vortex and delays the passage of the air bubbles to the outlet fluid pathway.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
42.
SYSTEM AND METHOD FOR SYRINGE PLUNGER ENGAGEMENT WITH AN INJECTOR
A plunger (326) for use with a syringe includes a plunger body (332) defining a central longitudinal axis (334) and having a proximal end (336), a distal end (338), and a circumferential sidewall (339) connecting the proximal end and the distal end. The plunger further includes at least one retaining member (368) associated with and extending proximally from the plunger body. The at least one retaining member has a first end connected to the plunger body, a second end proximal to the first end and radially and resiliently deflectable relative to the first end, and at least one catch (374) on the second end. A fluid injector system includes a piston (400) having a plunger engagement mechanism configured for interacting with the at least one retaining element of the plunger to releasably engage the plunger for reciprocally driving the plunger within a barrel of the syringe.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/315 - Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod; Appliances on the rod for facilitating dosing
43.
SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR CONTROLLING A FLUID INJECTION SYSTEM BASED ON HYDRAULIC RESISTANCE
A system for controlling a fluid injection system is disclosed. The system includes at least one processor programmed or configured to determine at least one characteristic of a power injection protocol, where the at least one characteristic of the power injection protocol is associated with a medical fluid involved in the power injection protocol, determine an estimated value of viscosity of the medical fluid based on the at least one characteristic of the power injection protocol, calculate a hydraulic resistance score based on the estimated value of viscosity of the medical fluid, and determine one or more motor controller gains of a motor of a powered fluid injector in the power injection protocol based on the hydraulic resistance score.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
44.
SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR PROVIDING QUICK RESPONSE (QR) CODES FOR INJECTION SYSTEMS
A system for providing a quick response (QR) code associated with an injection system is disclosed. The system includes the injection system and at least one processor. The at least one processor is programmed or configured to: receive data associated with the injection system; generate a network resource based on the data associated with the injection system, wherein, when generating the network resource, the at least one processor is programmed or configured to encode the data associated with the injection system into the network resource; generate a QR code based on the network resource; and display the QR code on a display screen of the injection system.
H04L 29/06 - Communication control; Communication processing characterised by a protocol
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
G06F 16/955 - Retrieval from the web using information identifiers, e.g. uniform resource locators [URL]
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
H04L 29/08 - Transmission control procedure, e.g. data link level control procedure
A fluid injector system (1000) is configured to perform an injection protocol. The fluid injector system includes a housing (11) and a controller (900) operatively associated with a user input device (40) and a fluid actuator (16). The controller includes at least one processor programmed or configured to determine an orientation of the housing, receive at least one signal from the user input device, determine a direction of fluid actuation based on the orientation of the housing and the at least one signal, and actuate the fluid actuator in the direction of fluid actuation. The direction of fluid actuation corresponds to at least one of actuating the fluid actuator to inject fluid from a fluid reservoir and actuating the fluid actuator to draw fluid into the fluid reservoir.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A fluid injector system includes at least one injector for pressurizing and delivering at least one fluid from at least one fluid reservoir, a first flexible tube having a first lumen, a second flexible tube having a second lumen, and a valve assembly configured to selectively and reversibly compress the first flexible tube and the second flexible tube to open and close the first lumen and the second lumen. The valve assembly includes a first anvil moveable between a retracted position in which the first lumen is at least partially open and an extended position in which the first anvil closes the first lumen, a second anvil moveable between a retracted position in which the second lumen is at least partially open and an extended position in which the second anvil closes the second lumen, and at least one eccentric cam rotatable to move the first anvil and the second anvil between the retracted and extended positions.
A system and method for promoting and safeguarding the wellbeing of patients in relation to a fluid injection may obtain patient data; determine, based on the patient data, an initial risk prediction for a patient for a fluid injection to be administered to the patient, the initial risk prediction including a probability that the patient experiences at least one adverse event in response to the fluid injection; provide, to a user device, before the fluid injection is administered to the patient, the initial risk prediction; determine, after the fluid injection is started, sensor data associated with the patient; determine, based on the sensor data determined after the fluid injection is started, a current risk prediction including a probability that the patient experiences the at least one adverse event in response to the fluid injection; and provide, to the user device, the current risk prediction.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
This disclosure relates to pre-fill ed syringes and their methods for use and injection. The embodiments provide a pre-filled syringe system for controlled depth of injection in a subject, including a pre-fill ed syringe having a needle tip and a plunger for injecting the contents of the pre-filled syringe; a housing for holding the pre-filled syringe and needle tip in a defined position for a depth of injection; and a needle shield mounted on the housing for releasable movement from a locked injection position to a shield position, wherein after the needle shield is moved into the locked injection position with the needle tip extended out of the needle shield and pre-filled syringe system, the needle can be inserted into the subject at a defined depth of injection. The embodiments further provide methods of injecting a subject using a pre-filled syringe system, including providing a pre-filled syringe system having a housing, a needle shield mounted on the housing, and a pre-filled syringe with a needle tip; moving the needle shield mounted on the housing into a locked injection position to extend the needle tip of the pre-filled syringe and system at a defined length out of the needle shield and pre-filled syringe system; inserting the needle tip of the pre-filled syringe and system into a subject at a defined injection depth, and injecting the contents of the pre-filled syringe and system into the subject.
A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion
49.
SYSTEM FOR AIR VOLUME CORRECTION BASED ON FLUID PRESSURE AND FLOW RATE
A method for determining a volume of one or more air bubbles in a fluid path includes initiating an injection procedure in which at least one medical fluid is injected into the fluid path, receiving an electrical signal from an air detector of the fluid injector system, wherein the electrical signal indicates the presence of one or more air bubbles in the fluid path, calculating a flow rate of fluid in the fluid path, determining a fluid pressure in the fluid path, determining a count value of the one or more air bubbles representative of a volume of the one or more air bubbles, and updating a cumulative counter with the count value of the one or more air bubbles. The cumulative counter is representative of a cumulative volume of air that has passed through the fluid path during the injection procedure.
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
A fluid injector system includes at least one syringe configured for injecting medical fluid and a fluid path assembly in fluid communication with the at least one syringe, the fluid path assembly including at least one air detection region. The system includes an air detector configured to detect one or more air bubbles in a fluid path associated with the air detection region, at least one shutoff valve at a distal end of the fluid path assembly, and at least one processor programmed or configured to actuate the shutoff valve in response to the air detector detecting the one or more air bubbles in the fluid path associated with the air detection region to prevent fluid flow out of the fluid path assembly. The fluid path assembly has a length greater than a distance that an air bubble can travel or expand during an actuation time of the shutoff valve.
A valve assembly for a fluid injector system includes a valve housing, a first port configured for fluid communication with a fluid injector, a second port, a third port, and a fourth port configured for fluid communication with a patient line. The valve assembly includes an air detection region associated with the first port, a fluid path length having a proximal end in fluid communication with the second port and a distal end in fluid communication with the third port, and a valve element defining a first fluid path and a second fluid path. The first fluid path provides fluid communication between the first and second ports in a delivery position of the valve housing. The second fluid path provides fluid communication between the third and fourth ports in the delivery position. The third port is isolated from the fourth port in a stop position of the valve housing.
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
A fluid mixing device for mixing a first injection fluid and a second injection fluid includes a first fluid inlet, a second fluid inlet, a mixing chamber in fluid communication with the first and second fluid inlets, and an outlet port in fluid communication with the mixing chamber. The first fluid inlet is configured to conduct the first injection fluid in a first direction and has a first redirecting surface. The second fluid inlet is configured to conduct the second injection fluid in a second direction along a different axis from the first direction and has a second redirecting surface. The mixing chamber is configured to mix the first injection fluid and the second fluid together. The mixture of the first injection fluid and the second injection fluid exits the fluid mixing device via the outlet port.
A fluid path connector for a medical fluid delivery system, the fluid path connector including a first connector element comprising a body, a first lumen, a first flexible leg, and a second flexible leg, and a second connector element comprising a body defining an undercut, a second lumen, a channel defined in the body, and at least one sealing element positioned within the channel, in which the first flexible leg comprises a first flange and the second flexible leg comprises a second flange, and in which, upon engagement of the first connector element with the second connector element, the first flange and the second flange engage with the undercut of the body of the second connector element to prevent disengagement of the first connector element and the second connector element.
The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the disclosed antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to oral naproxen sodium tablets comprising roller-compacted granules, methods of preparing thereof, and methods of using thereof. The naproxen sodium tablets are formulated for and prepared by dry granulation methods, specifically roller compaction. The combination of dry granulation compatible excipients with roller compaction methods results m naproxen sodium tablets that exhibit an enhanced dissolution profile and shorter disintegration time as compared to commercially available oral naproxen sodium tablets prepared by standard wet granulation methods.
A fluid injector system configured for use in administering at least one fluid to a patient, the fluid injector system including at least one image capture device configured for capturing image data in an environment surrounding the fluid injector system; and a control device comprising at least one processor programmed or configured to receive, with the at least one processor, the image data captured by the at least one image capture device; determine, with the at least one processor, whether the received image data comprises at least one predetermined characteristic; and perform, with the at least one processor, at least one action in response to determining whether the received image data comprises at least one predetermined characteristic.
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/42 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
A system and method are disclosed for user- or system-configurable and adaptive pressure limiting behavior in fluid injection systems/devices. A fluid injector system may include at least one fluid injector device, at least one user interface, and a control device comprising at least one processor. The at least on processor may be programmed or configured to: receive a maximum pressure limit for an injection procedure, receive a programmed fluid flow rate for the injection procedure, receive a maximum fluid flow rate reduction input for the injection procedure, wherein the maximum fluid flow rate reduction input is selected by a user via the at least one user interface, and receive a pressure limit sensitivity input for the injection procedure, wherein the pressure limit sensitivity input is selected by the user via the at least one user interface. The at least one processor may also be configured to control the at least one fluid injector device to perform the injection procedure based on the maximum pressure limit, the programmed fluid flow rate, the maximum fluid flow rate reduction input, and the pressure limit sensitivity input.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
59.
SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR OCCLUSION DETECTION AND IMPROVED PRESSURE LIMITING BEHAVOIR FOR FLUID INJECTOR DEVICES
A system, method, and computer program product are disclosed for occlusion detection and/or pressure limiting in a fluid injector system. A fluid injector system may include at least one fluid injector device, one or more drive components, and a control device. The control device may comprise at least one processor programmed or configured to: provide instructions to the fluid injector system to deliver fluid from the at least one fluid injector device at a predetermined fluid flow rate, determine a first fluid pressure measurement within the at least one fluid injector device at a first time, determine a second fluid pressure measurement within the at least one fluid injector at a second time, determine a pressure differential between the first fluid pressure measurement and the second fluid pressure measurement, calculate a change in compliance volume of the at least one fluid injector device based on the determined pressure differential, compare the calculated change in compliance volume with the predetermined fluid flow rate, repeat the steps throughout the fluid injection procedure, and determine whether an occlusion or a partial occlusion has occurred downstream of the at least one fluid injector device.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
60.
SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR SMART FLUID INJECTOR PERFORMANCE MONITORING
A method, system, and computer program product are disclosed for performance monitoring of a smart fluid injector system having at least one sensor configured for detecting operation data. The operation data includes one or more operation parameters associated with at least one of: one or more drive components of the fluid injector system and at least one disposable component configured for use with the fluid injector system. The fluid injector system further includes a control device having at least one processor programmed or configured to: receive the operation data, and determine a component status for at least one of: the drive component(s), the disposable component(s), and administration line(s) by comparing the received operation data with stored operation data. The component status includes one or more predictions of an operation failure or a misuse of at least one of: the drive component(s), the disposable component(s), and administration line(s).
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
61.
SYSTEM AND METHOD FOR FLUID DELIVERY USING PRESSURE-BASED MOTOR CONTROL FOR FLUID INJECTOR DEVICES
A system, method, and computer program product are disclosed for a flow rate algorithm that utilizes changes in fluid pressure over a set time interval to calculate a true flow rate compared to a programmed flow rate, determine any over-delivery or under-delivery in the amount of fluid delivered over the set time interval, compensate for any determined over- delivery or under-delivery in the fluid flow rate over a subsequent set time interval, and repeat the flow rate algorithm for a series of subsequent set time intervals over the duration of a fluid injection procedure.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
The present disclosure is directed to capsules, for example, softgel capsules for oral administration that have on their surface laser etching that penetrates at least partially into the surface of the capsule, reduces the structural integrity of the capsule while preventing exposure of the interior contents to the outside environment, and increases the rate of release of active ingredients contained within.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
63.
PRESSURE JACKETS AND SYRINGE RETENTION FEATURES FOR ANGIOGRAPHY FLUID INJECTORS
An assembly for retaining a pressure jacket (134) and a syringe (132) on a fluid injector, the assembly including a base plate (1902) comprising a body (1904); at least a first retaining arm (1910a) and a second retaining arm (1910b) operatively mounted on the body of the base plate, the first retaining arm having a first retaining surface at a distal end thereof and the second retaining arm having a second retaining surface at a distal end thereof, wherein the first retaining surface and the second retaining surface are configured for abutting a distal surface of at least one of the pressure jacket and the syringe; a linkage assembly operatively connected to at least one of the first retaining arm and the second retaining arm, wherein the linkage assembly is configured to move at least one of the first retaining arm and the second retaining arm between at least a first open position and a closed position.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
An administration line for use with a fluid injector system includes a fluid verification module configured to be in operative communication with a housing of the fluid injector system such that the fluid injector system can determine a status of the administration line. The fluid verification module includes a body defining an inlet port, an outlet port, and a fluid channel extending from the inlet port to the outlet port; a first tubing section connected to the inlet port; and a second tubing section connected to the outlet port.
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
The present invention is directed to a palatable soft-chew veterinary composition comprising at least one active agent, at least one wetting agent, and at least one palatant or flavorant. The present invention also provides methods for controlling or treating a condition in an animal comprising administering the palatable composition to an animal in need thereof.
The present invention is directed to a palatable granular veterinary composition comprising at least one active agent, at least one wetting agent, and at least one palatant or flavorant. The present invention also provides methods for controlling or treating a condition in an animal comprising administering the palatable composition to an animal in need thereof.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A fluid container having a proximal end having an end wall, a distal end having an open-ended neck, and a sidewall extending between the proximal end and the distal end along a longitudinal axis is described. A localized crystallinity of a polymeric material of the fluid container of at least a first region of the fluid container is greater than a crystallinity of a polymeric material of the fluid container of at least a second region. Examples of fluid containers include medical fluid containers, such as medical bottles and syringes, including rolling diaphragm-type syringes, and commercial beverage containers. Articles of manufacturer formed form a polymeric material and having regions with increased localized polymeric crystallinity are also described.
B29C 49/00 - Blow-moulding, i.e. blowing a preform or parison to a desired shape within a mould; Apparatus therefor
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
B32B 7/02 - Physical, chemical or physicochemical properties
B32B 25/14 - Layered products essentially comprising natural or synthetic rubber comprising copolymers in which synthetic rubber constituents predominate
B32B 25/16 - Layered products essentially comprising natural or synthetic rubber comprising polydienes or poly-halodienes
B32B 25/18 - Layered products essentially comprising natural or synthetic rubber comprising butyl or halobutyl rubber
B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
The present application provides materials and methods for controlling gene editing. The present application also provides materials and methods for controlling transcriptional expression of guide RNAs and/or post-transcriptional expression of Cas nuclease.
Provided is a method for delivering a medical fluid. The method includes administering a test injection at a preselected total volumetric flowrate for a preselected duration. The preselected total volumetric flowrate of the test injection is substantially maintained throughout the preselected duration of the test injection and is substantially similar to an anticipated total volumetric flowrate of the fluid to be administered during at least a first phase of a diagnostic injection protocol. The method further includes performing a test scan of one or more regions of interest of the patient, determining a patient response function for the patient for each of the one or more regions of interest based, at least in part, on the enhancement output, and determining a diagnostic injection protocol based at least in part upon the patient response function from each of the one or more regions of interest.
A clamp for regulating fluid flow in a flexible tube of a fluid injector system including an anvil and a cam assembly is described. The anvil includes a receiving surface for receiving the flexible tube. The cam assembly includes either a solid cam or a rollable outer race and an inner race having a central axis and a rotation axis spaced apart from the central axis. The inner race is rotatable relative to the outer race. Rotation of the inner race about the rotation axis rolls the outer race in a direction relative to the receiving surface of the anvil to reversibly compress the flexible tube between the outer race and the anvil.
Provided are topical analgesic spray compositions and topical analgesic spray concentrates containing menthol and camphor in high concentrations. The present disclosure also provides organoleptic compositions for use in the topical analgesic spray compositions and concentrates to provide enhanced sensory experience and long-lasting pain-relief.
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/045 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
Provided are topical analgesic gel compositions having relatively high payloads of menthol and camphor by micro-emulsion technology and methods of preparing topical analgesic gel compositions having relatively high payloads of menthol and camphor. Topical analgesic gel compositions may include from 12 to 16 vvt. % menthol; from 4 to 8 wt % camphor; from. 0.1 to 2 wt. % carbomer; and 60 to 70 wt. % solvent. Topical analgesic gel compositions can have a viscosity from 60,000 to 110,000 centipoise.
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/045 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
Provided are topical analgesic compositions and methods of preparing topical analgesic compositions comprising a stable nano-encapsulating matrix film. The topical analgesic compositions and methods of preparing topical analgesic compositions may be suited for roll-on applicators. Topical analgesic compositions may include 12 to 16 wt. % menthol; 4 to 8 wt. % camphor; 2 to 15 wt. % film-forming polymer; and 50 to 70 wt. % solvent. To be used in a roll-on applicator, the topical analgesic composition has a viscosity from 800 to 1400 centipoise.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/045 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
Disclosed are new nucleic acid base-editing systems that are based on a fusion protein comprising a) an RNA-programmable nucleic acid recognition domain or other suitable nucleic acid recognition domain, b) a nucleobase editing domain, and c) a domain capable of binding to apurinic/apyrimidinic (AP) sites or abasic sites within single- or double-stranded DNA, and their uses in genome editing and other applications.
Described are systems and methods for assessing a likelihood of chronic thromboembolic pulmonary hypertension (CTEPH) within a subject patient based upon an analysis of characteristics indicative of chronic thromboembolic pulmonary hypertension within an imaging study of the subject patient. The systems and methods can identify characteristics of one or more anatomical structures within a cardiac region of the subject patient indicative of CTEPH, characteristics of a pulmonary vasculature of the subject patient indicative of CTEPH, and characteristics of a chronic abnormality in a lung of the subject patient indicative of CTEPH. The systems and methods can assess these characteristics to compute the likelihood of CTEPH within the subject patient.
Described herein are novel systems for targeting, editing or manipulating DNA in a cell, using novel M- SmallCas9 nucleases and variants thereof. The M-SmallCas9 nucleases are derived from wildtype or parental small type II CRISPR Cas9 endonucleases, and display improved fidelity compared to parental type II CRISPR Cas9 enzymes in combination with a simple PAM sequences and are small endonuclease size.
ex vivoin vivoin vivo. Also provided herein, in some embodiments, are materials and methods for knocking in a coding sequence encoding a synthetic FVIII having a B domain substitute into a genome.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The present disclosure relates generally to topical analgesic compositions comprising nonsteroidal anti-inflammatory drugs, and more specifically to topical gel compositions of naproxen in combination with select neutralizing agents, thereby having enhanced skin permeation and skin retention properties as well as improved aesthetics upon application and drying.
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
79.
MECHANISMS FOR PREVENTING RECONNECTION OF CONNECTORS INTENDED FOR SINGLE USE
A single-use connector configured to be removably connected to a reusable connector includes a hollow, tubular housing having an open proximal side opposite a distal side along a longitudinal length of the housing and at least one guard member connected to the tubular housing. The at least one guard member is configured to transition between an open position, in which the single-use connector can be connected to the reusable connector, and a closed position in which the guard member prevents the single-use connector from being connected to the reusable connector. Disconnecting the single-use connector from the reusable connector causes the at least one guard member to transition from the open position to the closed position. A single-use disposable set (SUDS) including a single-use connector and at least use guard member for preventing reconnection of the connector to a reusable connector or fluid port is also disclosed.
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
The present disclosure relates generally to novel lipid nanoparticle (LNP)-based compositions useful for, e.g., the delivery of a site-specific endonuclease or a nucleic acid molecule encoding same, into a target cell. Some embodiments of the disclosure relate to compositions and methods for editing the genome of a cell, which involve contacting the cell with an LNP composition as described herein.
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
This disclosure relates to methods for use in inactivating viruses. The virus inactivation methods are for use in continuous process manufacturing of a biologic such as an antibody, and include separating an eluate using a column, subjecting said eluate to an orthogonal treatment of low pH and detergent simultaneously wherein, the time for viral inactivation is reduced. In addition, the detergent can be added to buffer system in purification process to achieve the same effect. The biologic in each treatment case is retained.
Stable dosage forms, preferably of pharmaceutical formulations, that include a solid or semi-solid polymeric mass, which entraps active ingredients and can be formulated for oral administration in a mould, preferably in a softgel capsule.
A frame for engaging at least two fluid containers includes: a first engagement member configured to secure at least a portion of one of the at least two fluid containers; a second engagement member configured to secure at least a portion of another one of the at least two fluid containers; and a body structure connected to the first engagement member and the second engagement member. The body structure is sized and shaped to index the at least two fluid containers with a powered injector system such that the at least two fluid injectors are held in an orientation and distance relative to each other for insertion into at least two pressure jackets associated with the powered injector system.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
85.
SYRINGE RETENTION FEATURE FOR FLUID INJECTOR SYSTEM
An injector system for delivering a medical fluid, the injector system including an injector configured to receive at least one syringe, the injector comprising at least one piston for releasably engaging and reciprocally driving a plunger or an end wall of the at least one syringe; and a syringe retaining interface comprising one or more retaining elements configured to engage at least a portion of a distal end portion of the at least one syringe to limit movement of the at least one syringe in a distal direction relative to the injector as the medical fluid is delivered from the reservoir via distal movement of the at least one piston.
A system for conducting a fluid injection procedure comprises: a loading device for filling containers with fluid; an information read/write device operatively associated with the loading device and configured to: read information related to the containers stored on information storage devices associated with the containers and write information related to an injection procedure and/or a patient to the information storage devices; and a fluid injector system configured to receive the containers after filling by the loading device and inject the contents of the containers of fluid into the patient. The loading device is configured to fill the containers with fluid based on the information related to the containers read from the information storage devices. The information read/write device is configured to write information to the information storage device. The fluid injector system is configured to read the information and use this information to program the fluid injector system.
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A fluid injector system includes a control device operatively associated with a first drive component configured to pressurize and inject a first fluid and a second drive component configured to pressurize and inject a second fluid. The control device includes at least one processor programmed or configured to: during a first phase of a multi-phase injection protocol, actuate at least the first drive component to inject the first phase; during the first phase of the injection protocol and prior to transitioning to a second phase of the injection protocol, actuate the second drive component to pressurize the second fluid relative to a pressure of the first fluid; and during the second phase of the injection protocol, actuate the second drive component to inject at least the second fluid so that a desired steady-state ratio of the first fluid and the second fluid in the second phase is reached.
A fluid injector system includes a control device operatively associated with each of two or more drive components configured to pressurize and inject a first fluid from a first fluid reservoir through a fluid conduit, and at least a second fluid from a second fluid reservoir through the fluid conduit. The fluid conduit is in selective fluid communication with the first and second fluid reservoirs. The control device has at least one processor programmed or configured to actuate a second drive component to pressurize and inject the second fluid through the fluid conduit, and while the second drive component is actuated, actuate a first drive component to introduce intermittent pulses of the first fluid to create a flow front interface between the first fluid and the second fluid in the fluid conduit to prevent backflow of the second fluid through the fluid conduit into the first fluid reservoir.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A fluid injector system configured to perform an injection protocol in connection with a diagnostic imaging procedure includes a memory for storing a predetermined pressure profile representative of pressure expected to be generated within an exemplary administration line by a priming fluid, and a control device operatively associated with a drive component to pressurize and inject at least one fluid through a subject administration line. The control device includes a processor configured to perform an operation including: actuating the drive component to prime the subject administration line; determining a distinct pressure profile indicative of a measurement of current pressure generated during the priming of the subject administration line; comparing the distinct pressure profile to the predetermined pressure profile; and determining, based on a result of the comparison, whether the subject administration line, prior to priming, contained at least one of a liquid or a gas as the extant fluid.
The present disclosure relates to an aqueous-based composition containing one or more natural polymers and two or more natural polyols, where the aqueous-based composition is formulated to inhibit microbial growth without utilizing any added artificial preservatives.
The present disclosure relates generally to pharmaceutical formulations of oxymetazoline and, more specifically, formulations of oxymetazoline containing one or more transition metal additives and having enhanced stability against degradation.
A cushioning member that includes a base, a plurality of protrusions extending from at least a portion of the base, the protrusions being configured to deform to provide cushioning; and an outer surface at least partially formed from distal ends of the protrusions, wherein at least a portion of a first protrusions is taller than an adjacent portion of a second protrusions so that the portion of the first protrusions deforms prior to the adjacent portion of the second protrusions in response to a pressure applied by a planar surface in contact with the outer surface of the cushioning member.
A removable insole for footwear, the removable insole includes a base, a plurality of walls extending from and curving along at least a portion of the base, the walls being configured to deform to provide cushioning, and an outer surface at least partially formed from distal ends of the walls, wherein at least a portion of a first wall is taller than an adjacent portion of a second wall so that the portion of the first wall deforms prior to the adjacent portion of the second wall in response to a pressure applied by a planar surface in contact with the outer surface of the cushioning member.
A rolling diaphragm syringe has a proximal end having an end wall, a distal end, and a sidewall extending between the proximal end and the distal end. The rolling diaphragm syringe further has a piston engagement portion protruding proximally from a central portion of the end wall, the piston engagement portion having a central axis, and a plurality of grooves recessed inward relative to an outer surface of the piston engagement portion. The grooves are spaced apart from each other in a direction about the central axis. The piston engagement portion is configured for engagement with at least one engagement element of a piston of a fluid injector at least during movement of the piston in a proximal direction.
A61M 5/315 - Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod; Appliances on the rod for facilitating dosing
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
95.
SYSTEM AND METHOD FOR AIR DETECTION IN FLUID INJECTOR
An injector system for delivering a medical fluid may include at least one syringe defining a reservoir operatively connected to a piston; and at least one processor programmed or configured to, based on an air check protocol for detecting air in the reservoir, determine a baseline value comprising baseline compressibility data for the at least one syringe of the injector system, deliver the first amount of the medical fluid from the reservoir; refill the reservoir with a second amount of the medical fluid; based on the air check protocol, perform an air check pressurization sequence by gathering air check compressibility data for the at least one syringe of the injector system; and based on the air check protocol, compare the air check compressibility data with the baseline compressibility data to determine a volume of air present in the reservoir.
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A fluid injector system includes at least one fluid reservoir having at least one interior surface and defining an internal volume, at least one actuator configured to change the internal volume of the at least one fluid reservoir, and at least one processor. The at least one processor may be programmed or configured to drive the actuator to at least partially fill the at least one fluid reservoir with a fluid from a fluid source, drive the actuator to generate a least a partial vacuum within the internal volume to dislodge one or more gas bubbles adhered to the at least one interior surface and to cause the one or more gas bubbles to coalesce into a coalesced bubble, and drive the actuator to expel the coalesced bubble from an outlet of the at least one fluid reservoir.
A fluid injector system has a controller for operably controlling the injection of contrast and/or saline into a patient. The controller allows a user to program a diagnostic injection procedure having one or more phases according to which the contrast and/or saline will be injected into the patient so as to effect enhancement of a region thereof during an imaging procedure. It further allows the user to program a test injection procedure to be performed prior to the diagnostic injection procedure. The test injection procedure is implementable as: (a) a variable single phase test injection in which the rate at which the saline is to be delivered is selectable prior to and may be varied during performance thereof; and/or (b) a multi-phase test injection in which the rate at which the saline is to be delivered is selectable for each phase of the multi-phase test injection prior to performance thereof.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
98.
FLEXIBLE DOSE ESTIMATION WITH USER-DEFINED VOLUMES
Described is a method of providing an estimate of radiation dose received by a patient during an imaging scan performed by an imaging system. The method includes receiving patient information about the patient, receiving scan data generated during the imaging scan of the patient by the imaging system, creating a virtual dose model of the patient based upon the patient information and the scan data, receiving a selection of a region of interest of the patient, performing a dose simulation on the virtual dose model of the patient or a portion thereof, and determining, based upon an outcome of the dose simulation, an estimate of the radiation dose received within the region of interest. The imaging scan can be a partial imaging scan of a portion of the patient. Also provided is a system and software for carrying out this method.
A fluid injector system includes a control device operably associated with at least one drive component for use in actuating a plurality of fluid containers in fluid communication with a patient through an administration line. The control device includes at least one processor programmed or configured to enable programming of a diagnostic injection protocol comprising one or more phases according to which at least one of the first and the second fluid containers are selectively actuatable by the at least one drive component to enable injection of at least one of a first fluid and a second fluid into the patient. The control device is further programmed or configured to enable selection and commencement of at least partial preloading into the administration line of at least one of the first fluid and the second fluid in accordance with the one or more phases of the diagnostic injection protocol.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A power injector system having a power injector for enabling delivery of fluid in an injection procedure to be performed on a patient may include one or more processors; a first user interface; and a second user interface. The first user interface and the second user interface may be configured to accept a plurality of user inputs associated with control of a plurality of operations of the power injector system and display information associated with the plurality of operations. One of the first user interface and the second user interface may be proximate to the power injector and the other may be remote from the power injector. The one or more processors may be programmed and/or configured to independently control the first user interface and the second user interface based on a first user input and a next user input received from the first user interface and/or the second user interface.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
patents
